Belzutifan (PT-2977; MK-6482; PT2977; MK6482; Welireg) is a novel, selective and orally bioavailable HIF-2α (hypoxia-inducible factor 2α) inhibitor that has gained FDA approval in 2021 for the treatment of von Hippel–Lindau disease-associated renal cell carcinoma. It inhibits HIF-2α with an IC50 of 9 nM. As a second-generation HIF-2α inhibitor, PT2977 has increased potency and improved pharmacokinetic profiles. Belzutifan is the first drug to be awarded an 'innovation passport' from the UK Medicines and Healthcare products Regulatory Agency (MHRA).

纯度：≥98%

CAS：1672668-24-4